Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Nivolumab in Patients (Pts) with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Clinical Outcomes from Extended Follow-up of a Phase 1 Study (CA209-039)

Stephen Ansell, MD PhD, Philippe Armand, MD PhD, John M. Timmerman, MD, Margaret A. Shipp, MD, M Brigid Bradley Garelik, MD, Lili Zhu, MS, Alexander M. Lesokhin, MD

Blood (2015) 126 (23): 583.

https://doi.org/10.1182/blood.V126.23.583.583

Published: 2015

Journal Articles

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)

Elias Jabbour, Hagop M. Kantarjian, Giuseppe Saglio, Juan Luis Steegmann, Neil P. Shah, Concepción Boqué, Charles Chuah, Carolina Pavlovsky, Jiří Mayer, Jorge Cortes, Michele Baccarani, Dong-Wook Kim, M. Brigid Bradley-Garelik, Hesham Mohamed, Mark Wildgust, Andreas Hochhaus

Blood (2014) 123 (4): 494–500.

https://doi.org/10.1182/blood-2013-06-511592

Published: 2014

Includes: Supplemental data

Journal Articles

Four-Year (Yr) Follow-Up Of Patients (Pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) Receiving Dasatinib Or Imatinib: Efficacy Based On Early Response

Jorge E. Cortes, MD, Andreas Hochhaus, MD, Dong-Wook Kim, MD, Neil P. Shah, MD, PhD, Jiri Mayer, MD, PhD, Philip Rowlings, MD, Hirohisa Nakamae, MD, PhD, M. Brigid Bradley-Garelik, MD, Hesham Mohamed, MD, Hagop M. Kantarjian, MD, Giuseppe Saglio, MD

Blood (2013) 122 (21): 653.

https://doi.org/10.1182/blood.V122.21.653.653

Published: 2013

Journal Articles

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)

Blood (2012) 119 (5): 1123–1129.

https://doi.org/10.1182/blood-2011-08-376087

Published: 2012

Journal Articles

Dasatinib (Versus Imatinib) In Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of Safety and Efficacy by Use of Baseline Medications In the DASISION Trial

Francois Guilhot, Hagop Kantarjian, MD, Neil P. Shah, Andreas Hochhaus, M. Brigid Bradley-Garelik, David Dejardin, Jorge E. Cortes, MD

Blood (2010) 116 (21): 2295.

https://doi.org/10.1182/blood.V116.21.2295.2295

Published: 2010

Journal Articles

Dasatinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) In the DASISION Trial: 18-Month Follow-up

Neil Shah, MD, Ph.D., Hagop Kantarjian, MD, Andreas Hochhaus, MD, Jorge E. Cortes, MD, M. Brigid Bradley-Garelik, MD, Chao Zhu, PhD, Michele Baccarani, MD

Blood (2010) 116 (21): 206.

https://doi.org/10.1182/blood.V116.21.206.206

Published: 2010

Journal Articles

Occurrence, Management, and Outcomes In Patients with Pleural Effusion During Dasatinib Treatment for Chronic-Phase Chronic Myeloid Leukemia (CML-CP) In the First-Line Setting: Analysis of the DASISION Trial

Kimmo Porkka, MD, PhD, Michele Baccarani, MD, Andreas Hochhaus, MD, Hagop Kantarjian, MD, Satu Mustjoki, MD, PhD, M. Brigid Bradley-Garelik, MD, Chao Zhu, PhD, Jorge E. Cortes, MD

Blood (2010) 116 (21): 2282.

https://doi.org/10.1182/blood.V116.21.2282.2282

Published: 2010

Journal Articles

Safety and Efficacy of Dasatinib Versus Imatinib by Baseline Cardiovascular Comorbidity In Patients with Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of the DASISION Trial

Giuseppe Saglio, MD, PhD, Andreas Hochhaus, MD, Ph.D., Jorge E. Cortes, MD, Hagop Kantarjian, MD, Michele Baccarani, MD, M. Brigid Bradley-Garelik, MD, David Dejardin, Neil P. Shah, MD, Ph.D.

Blood (2010) 116 (21): 2286.

https://doi.org/10.1182/blood.V116.21.2286.2286

Published: 2010

Journal Articles

Safety and Efficacy of Dasatinib (DAS) Vs. Imatinib (IM) by Baseline Comorbidity In Patients with Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of the DASISION Trial.

H. Jean Khoury, MD, FACP, Jorge E. Cortes, MD, Hagop Kantarjian, MD, Michele Baccarani, MD, Neil P. Shah, MD, Ph.D., M. Brigid Bradley-Garelik, MD, David Dejardin, Andreas Hochhaus, MD

Blood (2010) 116 (21): 3421.

https://doi.org/10.1182/blood.V116.21.3421.3421

Published: 2010

Journal Articles

Dasatinib Compared with Imatinib In Newly Diagnosed Chronic Myelogenous Leukemia In Chronic Phase (CML-CP):Results of Japanese Subset Analysis In DASISION Trial.

Michinori Ogura, MD, PhD, Hirohisa Nakamae, MD, PhD, Shin Fujisawa, MD, PhD, Kenichi Ishizawa, MD, Masafumi Taniwaki, MD, PhD, Atae Utsunomiya, MD, PhD, Kosei Matsue, MD, PhD, Kazuo Tamura, MD, Kensuke Usuki, MD, PhD, Mitsune Tanimoto, MD, PhD, Yoji Ishida, MD, PhD, Hideki Akiyama, MD, PhD, Rika Sakai, MD, PhD, Masanobu Kasai, MD, PhD, Masayuki Hino, MD, PhD, Kyoji Ueda, MD, PhD, Taku Seriu, MD, PhD, M. Brigid Bradley-Garelik, MD, Chao Zhu, PhD

Blood (2010) 116 (21): 4484.

https://doi.org/10.1182/blood.V116.21.4484.4484

Published: 2010

Journal Articles

Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up

Hagop Kantarjian, Jorge Cortes, Dong-Wook Kim, Pedro Dorlhiac-Llacer, Ricardo Pasquini, John DiPersio, Martin C. Müller, Jerald P. Radich, H. Jean Khoury, Nina Khoroshko, M. Brigid Bradley-Garelik, Chao Zhu, Martin S. Tallman

Blood (2009) 113 (25): 6322–6329.

https://doi.org/10.1182/blood-2008-11-186817

Published: 2009

Journal Articles

Dasatinib 140 Mg Once Daily (QD) Has Equivalent Efficacy and Improved Safety Compared with 70 Mg Twice Daily (BID) in Patients with Imatinib-Resistant or -Intolerant Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 2-Year Data from CA180- 035

Richard A. Larson, MD, Oliver G. Ottmann, MD, Neil P. Shah, MD, PhD, Michael B. Lilly, MD, Josy M. Reiffers, Aude Charbonnier, Gerhard Ehninger, MD, M. Brigid Bradley-Garelik, Chao Zhu, Giovanni Martinelli, MD

Blood (2008) 112 (11): 2926.

https://doi.org/10.1182/blood.V112.11.2926.2926

Published: 2008

Journal Articles

Dasatinib 140 Mg Once Daily (QD) Demonstrates Equivalent Efficacy and Improved Safety Compared with 70 Mg Twice Daily (BID) in Patients with Accelerated Phase Chronic Myeloid Leukemia (CML-AP): 2-Year Follow-up Data from CA180-035

Hagop M. Kantarjian, MD, Dong-Wook Kim, MD, PhD, Pedro Dorlhiac-Llacer, Ricardo Pasquini, Nina Khoroshko, John F. DiPersio, MD, PhD, Martin C Müller, MD, M. Brigid Bradley-Garelik, Chao Zhu, Martin S. Tallman, MD

Blood (2008) 112 (11): 3224.

https://doi.org/10.1182/blood.V112.11.3224.3224

Published: 2008

Journal Articles

Dasatinib 140 Mg Once Daily (QD) Demonstrates Equivalent Efficacy and Improved Safety Compared with 70 Mg Twice Daily (BID) in Patients with Chronic Myeloid Leukemia in Blast Phase (CML-BP): 2-Year Data from CA180-035

Giuseppe Saglio, MD, Hagop M. Kantarjian, MD, Andreas Hochhaus, MD, Yeow Tee Goh, MD, Tamas Masszi, MD, PhD, Ricardo Pasquini, Frederic Maloisel, M. Brigid Bradley-Garelik, Chao Zhu, Herve Dombret, MD, PhD, FRCP

Blood (2008) 112 (11): 3226.

https://doi.org/10.1182/blood.V112.11.3226.3226

Published: 2008

NARROW

Nivolumab in Patients (Pts) with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Clinical Outcomes from Extended Follow-up of a Phase 1 Study (CA209-039)

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)

Four-Year (Yr) Follow-Up Of Patients (Pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) Receiving Dasatinib Or Imatinib: Efficacy Based On Early Response

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)

Dasatinib (Versus Imatinib) In Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of Safety and Efficacy by Use of Baseline Medications In the DASISION Trial

Dasatinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) In the DASISION Trial: 18-Month Follow-up

Occurrence, Management, and Outcomes In Patients with Pleural Effusion During Dasatinib Treatment for Chronic-Phase Chronic Myeloid Leukemia (CML-CP) In the First-Line Setting: Analysis of the DASISION Trial

Safety and Efficacy of Dasatinib Versus Imatinib by Baseline Cardiovascular Comorbidity In Patients with Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of the DASISION Trial

Safety and Efficacy of Dasatinib (DAS) Vs. Imatinib (IM) by Baseline Comorbidity In Patients with Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of the DASISION Trial.

Dasatinib Compared with Imatinib In Newly Diagnosed Chronic Myelogenous Leukemia In Chronic Phase (CML-CP):Results of Japanese Subset Analysis In DASISION Trial.

Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up

Dasatinib 140 Mg Once Daily (QD) Has Equivalent Efficacy and Improved Safety Compared with 70 Mg Twice Daily (BID) in Patients with Imatinib-Resistant or -Intolerant Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 2-Year Data from CA180- 035

Dasatinib 140 Mg Once Daily (QD) Demonstrates Equivalent Efficacy and Improved Safety Compared with 70 Mg Twice Daily (BID) in Patients with Accelerated Phase Chronic Myeloid Leukemia (CML-AP): 2-Year Follow-up Data from CA180-035

Dasatinib 140 Mg Once Daily (QD) Demonstrates Equivalent Efficacy and Improved Safety Compared with 70 Mg Twice Daily (BID) in Patients with Chronic Myeloid Leukemia in Blast Phase (CML-BP): 2-Year Data from CA180-035

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only